INS and COVID-19: Because DPP-4 inhibitors are less effective at lowering blood glucose than other diabetes medications, we were concerned that patients prescribed DPP-4 inhibitors might have had less severe diabetes., To address this potential bias, we examined whether COVID-19 severity differed based on insulin use.